Loading...
•
Mar 31, 2021
Pliant Therapeutics Q1 2021 Earnings Report
Pliant Therapeutics reported first quarter 2021 financial results and provided a corporate update.
Key Takeaways
Pliant Therapeutics reported a net loss of $22.9 million for the first quarter of 2021, compared to a net income of $11.0 million for the prior-year quarter. Research and development expenses increased to $18.5 million, and general and administrative expenses rose to $6.6 million. As of March 31, 2021, the company had $264.1 million in cash, cash equivalents, and short-term investments.
PLN-74809 Phase 2a PET imaging trial preliminary data expected in the first half 2021.
PLN-74809 Phase 2a INTEGRIS trial in idiopathic pulmonary fibrosis (IPF) continued to build momentum, currently on track to complete enrollment by the end of 2021.
PLN-74809 Phase 2a INTEGRIS trial in primary sclerosing cholangitis (PSC) continued to advance, currently on track to complete enrollment in the first half 2022.
Successful completion of PLN-1474 Phase 1 trial and transfer of PLN-1474 to Novartis.
Forward Guidance
The Company believes it has sufficient funds to meet its operating and capital requirements into 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...